What is Aesthetics Biomedical?
Aesthetics Biomedical Inc. operates at the intersection of dermatology and advanced engineering, specializing in high-precision aesthetic technologies. The company is best known for the Vivace Ultra Vision, a sophisticated RF microneedling system that integrates real-time ultrasound imaging to deliver highly personalized skincare outcomes. Beyond its flagship hardware, the firm maintains a vertically integrated ecosystem through its SoME Skincare line, which provides autologous topical treatments designed to complement professional-grade procedures. By focusing on the synergy between clinical-grade devices and home-care maintenance, Aesthetics Biomedical addresses the growing demand for evidence-based, personalized aesthetic interventions among medical professionals and their patients.
How much funding has Aesthetics Biomedical raised?
Aesthetics Biomedical has raised a total of $1.1M across 2 funding rounds:
Private Equity
$700K
Debt
$350K
Private Equity (2016): $700K, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in Aesthetics Biomedical
Undisclosed Investor
A private equity firm focused on long-term capital appreciation and strategic growth within the healthcare and medical device sectors.
PPP
Public-Private Partnership
Strategic Partner
An industry-aligned investor providing capital and market access to accelerate the commercialization of breakthrough aesthetic technologies.
What's next for Aesthetics Biomedical?
With the successful acquisition of $0, Aesthetics Biomedical is poised to enter a new phase of enterprise-level scaling. The company's strategic roadmap likely involves the further integration of AI-driven diagnostics into its existing hardware portfolio and the expansion of its distribution network to capture a larger share of the global medical aesthetics market. As the firm transitions from a specialized technology developer to a broader platform provider, the focus will remain on maintaining clinical efficacy while optimizing the patient experience. Future growth will be driven by continued investment in R&D, ensuring that their combination therapies remain at the forefront of the industry's technological evolution.
See full Aesthetics Biomedical company page
